

Special Issue

Kinase Inhibitor Chemistry

Message from the Guest Editor

The development of therapeutic agents that target the inhibition of kinases has proven to be a fruitful endeavor. More than two dozen agents have been approved by the U. S. FDA in the last fifteen years. While there is no longer a question as to whether kinases are valid targets, there are still a myriad of approaches for pursuing inhibitors that span selectivity and reversibility parameters. Additionally, the utility of kinase inhibitors has been demonstrated in a variety of indications, from cancer to inflammation and pulmonary disease. This Special Issue aims to highlight recent results in the identification and optimization of kinase inhibitors in the continued search for new medicinal agents.

Guest Editor

Prof. Dr. James W. Leahy

Chemistry Department, University of South Florida, Tampa, FL, USA

Deadline for manuscript submissions

closed (15 August 2016)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/4696

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).